Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16

Faezeh Ghasemi1, Sina Rostami2, Maryam Sadat Nabavinia3, *Zahra Meshkat4
1. Dept. of New Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. Dept. of Biology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, Iran
3. Dept. of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4. Antimicrobial Resistance Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

ABSTRACT

Background: Human papillomavirus (HPV) is responsible for the development of cervical neoplasia. Infection with human papillomavirus type 16 (HPV-16) is a major risk factor for the development of cervical cancer. The virus encodes three oncoproteins (E5, E6 and E7), of which, the E7 oncoprotein is the major protein involved in cell immortalization and transformation of the infected cells. The aim of the current study was to develop Michigan Cancer Foundation 7 (MCF7) cells, which could stably express E7 protein of HPV type 16.

Methods: E7 gene of HPV type 16 was introduced into MCF7 cells by Lipofectamine 2000 reagent and the transfected cells were treated with G418 antibiotic. After antibiotic selection of the transfected cells, stable expression of E7 gene of HPV16 was confirmed by reverse transcriptase polymerase chain reaction (RT-PCR).

Results: Antibiotic selections of transfected cells were performed and transfected cells were alive in cytotoxic concentration of the antibiotic. RNA was extracted from transfected cells and E7 gene of HPV16 was amplified by RT-PCR method and a 350-bp band corresponds to E7 was observed.

Conclusion: Results confirmed the stable transfection of cells. The stably transfected cells can be used as a useful tool in future studies on HPV16 and cancers caused by this virus.

KEY WORDS
HPV-16
E7 gene
MCF7
Stable Expression
RT-PCR

ARTICLE INFO
Received 30 Dec 2014;
Accepted 05 Jan 2015;

Introduction

Papillomaviruses lack an envelope. Its nucleocapsid has icosahedral symmetry and is 52-55 nm in size (1). Papillomaviruses are very specific and show tropism for squamous epithelial cells (2). These viruses produce epithelial squamous and fibroepithelial tumor in their natural host (2, 3). Several types of HPVs may infect female genital tract and are capable of inducing cervical dysplasia in infected women (4).
More than 100 types of HPV have been found. Based on their ability to cause cancers, they have been classified as high-risk and low-risk HPVs (5).

HPV type 16 is considered to be in high-risk group and is responsible for more than half of cases of cervical cancers (6). HPV has a small circular genome of 8 kb in length; it contains two structural glycoproteins and six nonstructural proteins (7). E7 is a small nuclear protein. The ORF of E7 of HPV type 16 encodes a 98-amino acid phosphorylated protein (8). The encoded protein, with its oncogenic properties, could be involved in the induction of cancer (9). E7, with its stable expression in HPV or in cells infected with HPV could infect cells moreover, through its interactions with intracellular proteins and binding to tumor suppressor protein, pRB is critical in the control of cell cycle. Functions of E7 includes making cells eternal activation of Cyc E-A proteins, inactivation of Rb, induction of apoptosis and inhibition of several CDKs, increasing the permeability of cells to external DNA, inducing mutagenesis and resolution or inactivation of tyrosine kinas enzyme (10). MCF7 is derived from human breast cancer cells. It was firstly extracted from malignant breast tumor of a 69-year old woman in 1970. It grows attached to the surface (11).

The aim of the current study was to develop MCF7 cells with stably expression of E7 gene of HPV type 16.

**Materials and Methods**

**Vector:** Eukaryotic expression plasmid containing E7 gene of HPV type 16 was evaluated in the present study.

**Cell line:** MCF7 cell line was used. This cell line was purchased from Pasteur Institute of Iran. Cells were cultured with Dulbecco’s modified Eagle’s medium DMEM (high glucose) containing 10% bovine serum albumin, 0.1 mM non-essential amino acids, 100 U/ml penicillin, 100µg/ml of streptomycin and 2 mM glutamine at 37 ºC under 5% CO2 condition.

**Determination of cytotoxicity of G418 antibiotic:** concentrations higher than 400 µg/ml resulted in the death of all cells. Unviable cells were detected by their globular and granulated appearance and their faint plasma membrane.

**Construction of MCF7 cells with stable expression of E7 gene**

First, MCF7 cells were cultured in two wells of a 6-well microplate containing rich medium. Following that, cells of one well were transfected with pcDNA3/E7 by Lipofectamine 2000 reagent, according to the manufacturer’s recommendations. The second well was chosen as a control (all steps were also carried out on the minus control well). After 48 hours of transfection, 20% of cells in each well were transferred to the corresponding adjacent wells and growth medium containing G418 (the minimum concentration needed for kill this cell line) was added. Cells were passaged each two days to a new medium containing antibiotic so that the non-transfected cells (lacking antibiotic resistant gene) were killed and only those with expression vectors remained. In other words, cell focuses were formed. At the time all cells in the minus control completely were killed, concentration of the antibiotic was doubled in order to kill non-transfected cells in test well. Cells were then transferred to cell culture flask and replacement of culture with the new culture containing G418 antibiotic was performed to produce the needed amount of cells.

**RT-PCR to assess the stable expression of E7**

Following construction of E7 cells, their stable expression were confirmed by RT-PCR. Briefly, total RNA was extracted using RNX-Plus (Cinnagen, Tehran, Iran). DNA contamination was removed by DNase I. After that, RT-PCR
was performed. Complementary DNA (cDNA) was synthesized for 1µg of RNA by using oligo-dT primers at 37 ºC. In the final step, PCR was carried out using E7 specific primers, as described previously (12).

**Results**

**Confirming the expression of the E7 of HPV type 16 by RT-PCR**

In order to determine the fatal concentration...
of antibiotic for MCF7 cells, after 24 hours, cell membranes were destroyed and no isolated cells were observed (Fig. 1). The fatal concentration of G418 antibiotic was 400µg/ml for MCF7 cells.

After transfection of MCF7 cells with E7 expression vector of HPV, antibiotic selection was performed using fatal concentration of G418. Antibiotic treatment was performed by 400 µg/ml antibiotic for 14 days to obtain a stable clone of the cells. After antibiotic selection, the resulted clone was treated by 2x fatal concentration of G418 (800 µg/ml) for more 14 days to confirm the strong expression of the E7 gene. The resulted clone after antibiotic selection is indicated in Figure 2 at stages A, B and C. Stage D indicates the final monolayer. In order to evaluate the expression of E7 in final monolayer cells, RT-PCR was performed by oligo-dT, and 350-bp band corresponds to E7 (Fig. 3).

Discussion

More than 100 types of HPVs have been suggested, among which, type 16 is the most common (13). Type 16 is associated with severe and lethal cervical cancers. In primary genital lesions, HPV-DNA is found mostly in its episomal form (14).

However, in cell lines of cervical cancers and malignant tumors, viral DNA is found in its integrated form (15). Integration induces a mechanism in which pre-malignant lesions develop to cervical cancer transformation and its development to malignancy (16).

In keratinocyte cell line, E6/E7 of type 16 makes cells immortal eternal and inhibits final differentiation of cells. Expression of E6/E7 of type 16 was performed with B-actin promoter in P1321plasmid. This was important in making keratinocyte cells immortal eternal (17). Considering the crucial role of pRB in cell cycle, inhibiting the action of this protein by mutations and its further interactions with oncogenic genes of HPV, would result in the reduction of its level in cancer cells (18). E7 binds to hypophosphsrylated pRB and inhibits its action. This promoter the cell cycle to the S phase and triggers the synthesis of DNA (19).

In low risk types of HPV such as types 6-11, the affinity of protein E7 to pRB is ten times less than that of the high-risk types of HPV (20). Low risk types of HPV have less efficiency in cell transformation (21).

Expression of E6-E7 in both cell lines (BT20-MCF7) is accompanied by an increase in the expression of a transcription factor (Id-1). Recent studies showed that Id-1 is a regulatory factor of breast cancer cells in terms of metastasis (22).

Oncoprotein E6-E7 increases the expression of Id-7 in MCF7 and BT20 cell lines. Furthermore, HPV type 16 was present in all breast cells (23).

In another study, coupled receptors and ErbB-2 oncoprotein E6, E7 HPV type 16 tumor geneses of breast cancer cells was observed. ErbB-2 receptor is over-expressed in 30% of human breast cancers and 50% of breast cancers are positive for HPV type 16 and 18 (24).

Oncoprotein ErB-2 and E4-E6 of HPV type 16 cause malignant changes in epithelial cells of the mouth. Moreover, E6 and E7 of HPV type 16 transform non-invasive breast cells to invasive. In order to evaluate the association of ErB-2 and E6-E7 with tumorgenesis, transgenic mice, which had ErB-2 and E4-E6 of HPV type 16 and human keratin 14 as promoter were designed. After six months, these mice have developed more severe breast cancer. In Syria, high associations between HPV infection and breast cancer have been proved (25).

In a cohort study on 113 patients with breast cancer, HPV types 16, 18, 31, 33 and 35 was observed in 8.84, 9.73, 0.67, 55, 75 % and 37.16% of samples with invasive breast cancer, respectively. Totally, 69 (61.6%) of 113 samples were positive for HPV. Among which, 24 (37.78%) were infected with more than one type of HPV. Besides, expression of E6 oncoprotein in high – risk HPV was associated with the expression of
Id-1 in almost all invasive breast cancer samples. Another study showed the association of ErbB-2 receptor and the oncoprotein E6 and E7 of HPV type 16 cause tumorigenesis of breast cells (25).

Survivin is a member of IAP apoptotic inhibitors, which controls cell cycle. The expression of this gene is low in normal cells (26). This gene is mostly expressed in embryological and tumor tissues. Temporary expression of E6, E7 of HPV type 16 with surviving gene promoter was studied in vitro (27). P53 reduces the expression of survivin. Transformation of E6, E7 of HPV in fibroblast cell lines increased endogenous expression of mRNA of survivin. This was performed in MCF7, HeLa and Soas2 cell lines (28).

In another study, E6, E7 of HPV type 16 inactivated CDKp27 and CDKp21 inhibitors. Thus, direct relationship between this protein and regulatory factors of cell cycle exist considering the association of E6 and E7 of HPV type16 and intracellular factors such as S4 subunit of 26S proteosome, the association of this protein and cell tumor genesis was suggested (27).

In the present study, MCF7 cells with stable expression of HPV 16 E7 protein were developed. MCF7 cells originated from human breast cancer and the designed model can use as a HPV positive breast cancer model in in vitro studies. In addition, the interaction between HPV E7 oncoprotein and activated human oncogenes of MCF7 cells can be studied in this model in future.

**Conclusion**

Considering there is no animal model for HPV, MCF7 cells stably expressing HPV type 16 E7 protein will be valuable in HPV studies to develop a tumoral model for HPV16 in laboratory animals and to evaluate their immunologic responses in animal model as antigen candidates for vaccine production. In addition, it can be used as a model for HPV 16 positive human breast cancers in future studies.

**Acknowledgment**

The authors would like to thank Prof. Zuhair Mohammad Hasan for discussion of strategic concepts. The authors indicate no potential conflicts of interest. There is no Financial Disclosure.

**References**

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
2. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87(11):796-802.
3. Fernandes J, Araújo J, Fernandes T. Biology and natural history of human papillomavirus infection. Open J Clin Trials 2013;5:1-12.
4. Koutsky P, Laura. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5S1):3-8.
5. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157(3):218-26.
6. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
7. Liaw K-L, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183(1):8-15.
8. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010;40(1):1-13.
9. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11(8):781-9.
10. Nichols AC, Dhaliwal SS, Palma DA, Basmaji J,
Chapeskie C, Dowthwaite S, et al. Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013;42(1):1-9.
11. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74.
12. Meshkat Z, Soleimanjahi H, Mahmoudi M, Hassan ZM, Mirshahabi H, Meshkat M, et al. CTL Responses to a DNA Vaccine Encoding E7 Gene of Human Papillomavirus Type 16 from an Iranian Isolate. Iran J Immunol 2008;5(2):82-91.
13. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-8.
14. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24:S26-S34.
15. Bresse X, Adam M, Largeron N, Roze S, Marty R. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France. Hum Vaccin Immunother 2013;9(4).
16. Petry KU, Luyten A, Justus A, Ifneter A, Strehlie S, Reinecke-Lüthge A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 2013;13(1):135.
17. Pontén J, Adami H, Friberg L, Gustafsson L, Miller A, Parkin M, et al. HPV and cervical cancer. Int J Cancer 1995;63(2):317-20.
18. Edwards TG, Helmus MJ, Koeller K, Bashkin JK, Fisher C. Human Papillomavirus Episome Stability Is Reduced by Aphidicolin and Controlled by DNA Damage Response Pathways. J Virol 2013;87(7):3979-89.
19. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003;77(2):1551-63.
20. Teissier S, Pang C, Thierry F. The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells. Oncogene 2010;29(36):5061-70.
21. Morandell D, Kaiser A, Herold S, Rostek U, Lechner S, Mitterberger MC, et al. The human papillomavirus type 16 E7 oncoprotein targets Myc-interacting zinc-finger protein-1. Virology 2012;422(2):242-53.
22. Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2012;422(1):114-24.
23. Ling M, Wang X, Tsao S, Wong Y. Down-regulation of Id-1 expression is associated with TGFβ1-induced growth arrest in prostate epithelial cells. Biochim Biophys Acta 2002;1570(3):145-52.
24. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel A, Al Moustafa A. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 2008;99(3):404-7.
25. Arroyo M, Bachechi S, Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol cell Biol 1993;13(10):6537-46.
26. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2004;92(2):212-6.
27. Borbély AA, Murvai M, Kónya J, Beck Z, Gergely L, Li F, et al. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol 2006;87(2):287-94.
28. Yan J, Yong W, Lei XIONG YY, Jia Rui W. Differential regulation of survivin by p53 contributes to cell cycle dependent apoptosis. Cell Res 2005;15(5):361-70.

How to cite this article:
Ghasemi F, Rostami S, Sadat Nabavinia M, Meshkat Z. Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16. Iran J Pathol. 2016; 11(1): 41 - 46.